Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
2024 · Journal of the National Comprehensive Cancer Network · 459 citations
https://doi.org/10.6004/jnccn.2024.0035
H
Hatem Soliman
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
278
Papers
12.2K
Citations
45
h-index
93
i10-index
Hatem Soliman is an academic researcher from Georgetown University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Advanced Breast Cancer Therapies & Breast Cancer Treatment Studies. The author has an h-index of 45, co-authored 237 publications.
ORCID: 0000-0001-6644-2264Papers by this author
worksNCCN Guidelines® Insights: Breast Cancer, Version 4.2023
2023 · Journal of the National Comprehensive Cancer Network · 409 citations
https://doi.org/10.6004/jnccn.2023.0031
Breast Cancer, Version 3.2013
2013 · Journal of the National Comprehensive Cancer Network · 191 citations
https://doi.org/10.6004/jnccn.2013.0098
A phase I study of indoximod in patients with advanced malignancies
2016 · Oncotarget · 141 citations
https://doi.org/10.18632/oncotarget.8216
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy
2017 · Breast Cancer Research · 115 citations
https://doi.org/10.1186/s13058-017-0807-8
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
2019 · Breast Cancer Research and Treatment · 88 citations
https://doi.org/10.1007/s10549-019-05226-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat